Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

EBS

Emergent Biosolutions Inc

Last Close
May 01 • 04:00PM ET
1.93
Dollar change
+0.05
Percentage change
2.66 		%
Held by: FNDA VTI IWM VXF PRFZ IWN AVUV VTWO VHT SCHA
IndexRUT P/E- EPS (ttm)-14.84 Insider Own4.05% Shs Outstand52.20M Perf Week-11.47%
Market Cap100.75M Forward P/E- EPS next Y-1.15 Insider Trans0.00% Shs Float50.09M Perf Month-10.65%
Income-757.20M PEG- EPS next Q-0.93 Inst Own78.06% Short Float11.77% Perf Quarter15.57%
Sales1.05B P/S0.10 EPS this Y60.19% Inst Trans-1.89% Short Ratio1.96 Perf Half Y-4.93%
Book/sh12.44 P/B0.16 EPS next Y53.63% ROA-30.28% Short Interest5.89M Perf Year-78.24%
Cash/sh2.14 P/C0.90 EPS next 5Y- ROE-74.34% 52W Range1.42 - 10.88 Perf YTD-19.58%
Dividend Est.- P/FCF- EPS past 5Y- ROI-68.24% 52W High-82.26% Beta1.24
Dividend TTM- Quick Ratio0.54 Sales past 5Y10.59% Gross Margin27.46% 52W Low35.92% ATR (14)0.18
Dividend Ex-Date- Current Ratio1.04 EPS Y/Y TTM-231.09% Oper. Margin-17.05% RSI (14)41.21 Volatility6.96% 8.04%
Employees1600 Debt/Eq1.35 Sales Y/Y TTM-6.32% Profit Margin-72.11% Recom3.00 Target Price5.00
Option/ShortYes / Yes LT Debt/Eq0.71 EPS Q/Q45.91% Payout- Rel Volume0.53 Prev Close1.88
Sales Surprise36.39% EPS Surprise160.20% Sales Q/Q-16.36% EarningsMay 01 AMC Avg Volume3.01M Price1.93
SMA20-7.94% SMA50-20.91% SMA200-37.33% Trades Volume1,603,492 Change2.66%
Date Action Analyst Rating Change Price Target Change
Mar-07-24Upgrade The Benchmark Company Hold → Buy $5
Nov-20-23Resumed JP Morgan Underweight
Aug-29-23Downgrade The Benchmark Company Buy → Hold
Apr-10-23Upgrade The Benchmark Company Hold → Buy $22
Mar-17-23Downgrade JP Morgan Neutral → Underweight $23 → $9
Nov-10-22Downgrade The Benchmark Company Buy → Hold
Apr-29-22Downgrade Cantor Fitzgerald Overweight → Neutral
Jan-20-22Upgrade The Benchmark Company Hold → Buy $77
Nov-08-21Downgrade The Benchmark Company Buy → Hold
May-05-21Downgrade Argus Buy → Hold
Show Previous Ratings
Today 06:15PM
Emergent BioSolutions Reports Surprising Q1 2024 Earnings, Exceeding Revenue and Net Income ...
(GuruFocus.com)
05:53PM
Emergent Biosolutions: Q1 Earnings Snapshot
(Associated Press Finance)
05:52PM
Narcan-Maker Emergent BioSolutions to Cut 300 Jobs, Close Facilities
(The Wall Street Journal)
04:57PM
Emergent BioSolutions Reports First Quarter 2024 Financial Results
(GlobeNewswire)
04:34PM
UPDATE 2-Emergent BioSolutions to lay off about 300 employees
(Reuters)
04:21PM Loading…
04:21PM
Emergent BioSolutions to cut 300 jobs
(Reuters)
04:10PM
Emergent BioSolutions Announces Strategic Operational Changes to Stabilize Financial Position
(GlobeNewswire)
11:03AM
Emergent BioSolutions Releases New Survey Findings Underscoring the Need to Continue Expanding Access & Increasing Awareness to Naloxone
(GlobeNewswire)
Apr-30-24 05:26PM
Emergent BioSolutions Announces Amendment to its Existing Credit Facility
(GlobeNewswire)
Apr-22-24 08:05AM
Emergent BioSolutions to Release First Quarter 2024 Financial Results & Conduct Conference Call on May 1, 2024
(GlobeNewswire) +5.88%
Apr-01-24 08:00AM
Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive
(GlobeNewswire) -9.09%
Mar-28-24 08:15AM
Emergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN Nasal Spray to Help Save Lives from the Ongoing Opioid Crisis
(GlobeNewswire)
Mar-25-24 08:05AM
Emergent BioSolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility
(GlobeNewswire) +5.39%
Mar-07-24 01:58PM
Emergent BioSolutions Inc (EBS) Reports Mixed Fourth Quarter and Full Year 2023 Financial Results
(GuruFocus.com) -15.03%
12:34PM
Emergent (EBS) Down 16% on Q4 Earnings Miss, Tops on Sales
(Zacks)
10:33AM Loading…
10:33AM
Emergent BioSolutions Inc. (NYSE:EBS) Q4 2023 Earnings Call Transcript
(Insider Monkey)
07:35AM
Q4 2023 Emergent BioSolutions Inc Earnings Call
(Thomson Reuters StreetEvents)
Mar-06-24 11:30PM
Emergent BioSolutions (EBS) Q4 2023 Earnings Call Transcript
(Motley Fool)
09:53PM
EBS Stock Earnings: Emergent BioSolutions Misses EPS, Misses Revenue for Q4 2023
(InvestorPlace)
05:55PM
Emergent Biosolutions (EBS) Reports Q4 Loss, Tops Revenue Estimates
(Zacks)
05:20PM
Emergent Biosolutions: Q4 Earnings Snapshot
(Associated Press Finance)
04:31PM
Emergent BioSolutions Reports Fourth Quarter 2023 Financial Results
(GlobeNewswire)
Feb-29-24 07:00AM
Emergent BioSolutions to Release Fourth Quarter & Full Year 2023 Financial Results, and Conduct Conference Call on March 6, 2024
(GlobeNewswire)
Feb-21-24 03:24PM
Why Is Emergent BioSolutions (EBS) Stock Up 70% Today?
(InvestorPlace) +78.29%
07:35AM
UPDATE 2-Emergent appoints former Bausch + Lomb CEO to head company
(Reuters)
07:06AM
Emergent names Joseph Papa as new CEO
(Reuters)
07:00AM
Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO
(GlobeNewswire)
Jan-17-24 11:55AM
Emergent extends shelf life of opioid overdose reversal drug Narcan
(Reuters) -5.42%
Jan-12-24 02:20PM
Emergent (EBS) Gets $235.8M DoD Contract for Anthrax Vaccine
(Zacks)
Jan-11-24 08:00AM
Emergent BioSolutions Awarded Procurement Contract Valued up to $235.8 Million to Supply BioThrax (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense
(GlobeNewswire)
07:30AM Loading…
Jan-09-24 07:30AM
Emergent BioSolutions to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024
(GlobeNewswire)
Dec-12-23 06:53AM
EBS Stock Earnings: Emergent BioSolutions Misses EPS, Beats Revenue for Q3 2023
(InvestorPlace)
Dec-11-23 10:05AM
Emergent Biosolutions (EBS) Reports Q3 Loss, Tops Revenue Estimates
(Zacks) -14.86%
09:03AM
Emergent Biosolutions: Q3 Earnings Snapshot
(Associated Press Finance)
Nov-29-23 11:56AM
Emergent (EBS) Gets $75M BARDA Contract for Anthrax Vaccine
(Zacks) +6.97%
Nov-28-23 06:59AM
Emergent BioSolutions Receives $75 Million Contract Option from BARDA to Procure Doses of CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted)
(GlobeNewswire)
Nov-24-23 07:30AM
Emergent BioSolutions Receives NYSE Notice Regarding Delayed Form 10-Q Filing
(GlobeNewswire)
Nov-09-23 01:19PM
Emergent BioSolutions Inc. (NYSE:EBS) Q3 2023 Earnings Call Transcript
(Insider Monkey)
Nov-08-23 11:00PM
Emergent BioSolutions (EBS) Q3 2023 Earnings Call Transcript
(Motley Fool) -6.36%
05:38PM
Emergent BioSolutions Reports Third Quarter 2023 Financial Results
(GlobeNewswire)
Oct-30-23 04:45PM
UPDATE: Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 8, 2023
(GlobeNewswire)
Oct-19-23 06:30AM
Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 2, 2023
(GlobeNewswire)
Oct-16-23 07:00AM
Emergent BioSolutions Partners with Emmitt Smith to Launch Ready to Rescue Campaign to Help Save Lives Amidst Rising Opioid Epidemic
(PR Newswire)
Oct-02-23 07:00AM
Emergent BioSolutions Names Two Pharmaceutical Industry Veterans to Board of Directors
(GlobeNewswire) -7.06%
Sep-07-23 11:30AM
Why Is Emergent Biosolutions (EBS) Down 22.6% Since Last Earnings Report?
(Zacks)
Aug-30-23 05:59AM
Emergent BioSolutions NARCAN® Nasal Spray Launches Over the Counter Making it Possible for Everyone to Help Save a Life from an Opioid Overdose Emergency
(GlobeNewswire) +11.55%
Aug-29-23 09:37AM
Oracle upgraded, Farfetch downgraded: Wall Street's top analyst calls
(The Fly) -7.92%
Aug-25-23 11:36AM
Emergent BioSolutions (EBS) Down 12% in a Week: Here's Why
(Zacks)
Aug-23-23 12:33PM
Moody's downgrades Emergent BioSolutions' credit rating, citing unpredictable revenue outlook
(American City Business Journals)
Aug-22-23 11:42AM
Why Emergent BioSolutions Stock Is Tumbling Today
(Motley Fool) -5.88%
Aug-21-23 06:00PM
Kenvue Set to Join S&P 500; Advance Auto Parts to Join S&P SmallCap 600
(PR Newswire)
Aug-17-23 09:57AM
Sonnet (SONN) Up as Ovarian Cancer Drug Enters Clinical Study
(Zacks)
09:35AM
Down -28.45% in 4 Weeks, Here's Why You Should You Buy the Dip in Emergent Biosolutions (EBS)
(Zacks)
Aug-16-23 09:35AM
Down -26.38% in 4 Weeks, Here's Why You Should You Buy the Dip in Emergent Biosolutions (EBS)
(Zacks)
Aug-09-23 09:26AM
Emergent (EBS) Q2 Earnings Miss Estimates, Revenues Beat
(Zacks) -17.78%
08:29AM
Q2 2023 Emergent BioSolutions Inc Earnings Call
(Thomson Reuters StreetEvents)
12:30AM
Emergent BioSolutions (EBS) Q2 2023 Earnings Call Transcript
(Motley Fool)
Aug-08-23 07:40PM
Emergent Biosolutions (EBS) Reports Q2 Loss, Tops Revenue Estimates
(Zacks)
06:29PM
Emergent Biosolutions: Q2 Earnings Snapshot
(AP Finance)
04:31PM
Emergent BioSolutions Reports Financial Results for Second Quarter 2023
(GlobeNewswire)
08:23AM
Emergent BioSolutions to lay off 400 as its scales back its contract manufacturing business
(American City Business Journals)
07:50AM
Emergent BioSolutions to lay off about 400 employees
(Reuters)
07:44AM
UPDATE 1-Emergent BioSolutions to lay off about 400 employees
(Reuters)
07:15AM
Emergent BioSolutions Announces Strategic Steps to Strengthen Core Business and Financial Position
(GlobeNewswire)
Aug-07-23 11:32AM
Drug, Biotech Stocks' Q2 Earnings on Aug 8: LLY, LGND & More
(Zacks)
Aug-04-23 09:21AM
4 Biotech Stocks Set to Outpace Q2 Earnings Estimates
(Zacks)
Aug-01-23 12:06PM
Gaithersburg's Emergent BioSolutions lands large federal contract to boost development of Ebola drug
(American City Business Journals) +14.97%
Jul-31-23 04:05PM
Emergent BioSolutions Awarded 10-Year BARDA Contract Valued at up to a Maximum of $704 Million for Advanced Development and Procurement of Ebanga Treatment for Ebola
(GlobeNewswire)
Jul-25-23 06:30AM
Emergent BioSolutions to Release Second Quarter 2023 Financial Results and Conduct Conference Call on August 8, 2023
(GlobeNewswire)
Jul-20-23 06:31PM
UPDATE 1-US FDA approves Emergent BioSolutions' anthrax vaccine
(Reuters)
06:15PM
US FDA approves Emergent BioSolutions' anthrax vaccine
(Reuters)
06:03PM
Emergent BioSolutions Receives U.S. FDA Approval of CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909, a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use
(GlobeNewswire)
Jun-27-23 05:30PM
Why Emergent BioSolutions Stock Dived by 9% Today
(Motley Fool) -8.95%
08:02AM
Emergent BioSolutions CEO Robert Kramer to retire immediately
(Reuters)
07:55AM
Emergent BioSolutions Announces CEO Transition
(GlobeNewswire)
Jun-26-23 05:30AM
Better Recovery-Story Buy: Emergent BioSolutions or Invitae?
(Motley Fool)
Jun-21-23 08:00PM
EBS: Raising target price to $8.00
(Argus Research)
11:30AM
Immunovant, Inc. (IMVT) Down 10.6% Since Last Earnings Report: Can It Rebound?
(Zacks)
Jun-09-23 08:20AM
Is Emergent BioSolutions Stock a Buy Now?
(Motley Fool)
Jun-08-23 11:30AM
Why Is Emergent Biosolutions (EBS) Down 21.4% Since Last Earnings Report?
(Zacks)
Jun-07-23 08:20AM
Down 75%, Can Emergent BioSolutions Turn Things Around?
(Motley Fool) +6.12%
Jun-05-23 09:39AM
Shareholders in Emergent BioSolutions (NYSE:EBS) are in the red if they invested three years ago
(Simply Wall St.)
May-17-23 06:21AM
New Strong Sell Stocks for May 17th
(Zacks)
May-15-23 06:27PM
Why Emergent BioSolutions Stock Inched Slightly Higher Today
(Motley Fool)
07:58AM
Emergent BioSolutions Finalizes Sale of Travel Health Business to Bavarian Nordic
(GlobeNewswire)
May-11-23 06:30AM
Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 25, 2023 at 9:00am EDT
(GlobeNewswire)
May-10-23 10:47AM
Emergent (EBS) Q1 Earnings Miss Estimates, Revenues Beat
(Zacks) +11.44%
08:53AM
Q1 2023 Emergent BioSolutions Inc Earnings Call
(Thomson Reuters StreetEvents)
07:48AM
Emergent BioSolutions share price sinks following Q1 earnings. But its betting big on Narcan.
(American City Business Journals)
03:00AM
Emergent BioSolutions (EBS) Q1 2023 Earnings Call Transcript
(Motley Fool)
May-09-23 06:15PM
Emergent Biosolutions (EBS) Reports Q1 Loss, Tops Revenue Estimates
(Zacks) +6.36%
04:05PM
Emergent BioSolutions Reports Financial Results For First Quarter 2023
(GlobeNewswire)
May-08-23 09:29AM
Biotech Stocks' Q1 Earnings on May 9: NVAX, EBS & More
(Zacks)
May-02-23 10:01AM
Emergent Biosolutions (EBS) Expected to Beat Earnings Estimates: Should You Buy?
(Zacks) -6.76%
Apr-26-23 08:00PM
EBS: Lowering target price to $7.00
(Argus Research) -5.17%
Apr-24-23 02:09AM
Weekly Biotech Pulse: Vaxxinity results, Biogen's FDA review, and more | Pro Recap
(Investing.com)
Apr-20-23 11:41AM
Emergent aims to price over-the-counter Narcan at about $50
(Reuters)
Apr-19-23 04:05PM
Emergent BioSolutions to Release First Quarter 2023 Financial Results and Conduct Conference Call on May 9, 2023
(GlobeNewswire)
09:00AM
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
(Zacks)
Apr-10-23 01:00PM
Emergent Biosolutions Upgraded After FDA Approves Narcan OTC Sales
(Barrons.com) +17.23%
Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The firm's products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV. Its business units include Vaccines and Anti-Infectives, Antibody Therapeutics, Devices, and Contract Development and Manufacturing. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Zoon Kathryn CDirectorJun 02 '23Sale8.351,83015,28049,971Jul 24 08:28 AM
Zoon Kathryn CDirectorMay 25 '23Sale8.381,70014,24651,801Jul 24 08:28 AM
open in screener | open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Open in Screener

APVO

Aptevo Therapeutics Inc

Last Close
May 01 • 04:00PM ET
0.9600
Dollar change
+0.2493
Percentage change
35.08 		%
APVO Aptevo Therapeutics Inc monthly Stock Chart
Held by: VXF
Index- P/E- EPS (ttm)-72.07 Insider Own0.61% Shs Outstand1.61M Perf Week40.64%
Market Cap1.55M Forward P/E- EPS next Y-8.07 Insider Trans0.00% Shs Float1.60M Perf Month-75.88%
Income-17.41M PEG- EPS next Q-12.85 Inst Own2.75% Short Float9.10% Perf Quarter-86.58%
Sales0.00M P/S- EPS this Y-1223.51% Inst Trans13.63% Short Ratio0.50 Perf Half Y-92.73%
Book/sh27.62 P/B0.03 EPS next Y59.98% ROA-63.16% Short Interest0.15M Perf Year-98.79%
Cash/sh10.50 P/C0.09 EPS next 5Y- ROE-123.54% 52W Range0.67 - 84.97 Perf YTD-87.95%
Dividend Est.- P/FCF- EPS past 5Y46.80% ROI-98.83% 52W High-98.87% Beta5.11
Dividend TTM- Quick Ratio2.64 Sales past 5Y-17.88% Gross Margin- 52W Low43.28% ATR (14)0.36
Dividend Ex-Date- Current Ratio2.64 EPS Y/Y TTM-191.12% Oper. Margin0.00% RSI (14)30.13 Volatility15.97% 15.84%
Employees40 Debt/Eq0.44 Sales Y/Y TTM-100.00% Profit Margin- Recom1.00 Target Price15.25
Option/ShortNo / No LT Debt/Eq0.44 EPS Q/Q57.76% Payout- Rel Volume20.03 Prev Close0.71
Sales Surprise- EPS Surprise32.17% Sales Q/Q- EarningsMar 06 BMO Avg Volume289.34K Price0.96
SMA20-37.64% SMA50-75.15% SMA200-92.06% Trades Volume5,796,365 Change35.08%
Date Action Analyst Rating Change Price Target Change
Nov-05-18Initiated Ladenburg Thalmann Buy
Oct-05-17Resumed Piper Jaffray Overweight $6
Apr-16-24 12:47PM
Aptevo (APVO) Stock Plummets 79% in a Week: Here's Why
(Zacks)
Apr-15-24 04:05PM
Aptevo Therapeutics Announces Closing of $4.6 Million Public Offering
(ACCESSWIRE) -7.35%
Apr-11-24 08:15AM
Why Is Aptevo Therapeutics (APVO) Stock Down 56% Today?
(InvestorPlace) -60.08%
08:00AM
Aptevo Therapeutics Announces Pricing of $4.6 Million Public Offering
(ACCESSWIRE)
Apr-10-24 09:00AM
Aptevo Therapeutics Provides Pipeline Update
(ACCESSWIRE) -26.38%
06:00AM Loading…
Mar-18-24 06:00AM
Aptevo Participating in The Springtime Partnering Event, a Bio-Europe Conference
(ACCESSWIRE) -8.12%
Mar-07-24 08:55AM
Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4
(ACCESSWIRE)
Mar-05-24 01:51PM
APVO Stock Earnings: Aptevo Therapeutics Beats EPS for Q4 2023
(InvestorPlace) -8.55%
08:05AM
Aptevo Therapeutics Reports 2023 Financial Results and Provides a Business Update
(ACCESSWIRE)
Mar-04-24 09:00AM
Aptevo Therapeutics Announces 1-for 44 Reverse Stock Split As Part of Nasdaq Compliance Plan
(ACCESSWIRE) -13.72%
Nov-14-23 08:05AM
Aptevo Therapeutics Reports 3Q23 Financial Results and Provides a Business Update
(ACCESSWIRE) +6.82%
Nov-01-23 07:45AM
Aptevo to Present at Bio-Europe Conference
(ACCESSWIRE)
Aug-10-23 08:05AM
Aptevo Therapeutics Reports 2Q23 Financial Results and Provides a Business Update
(ACCESSWIRE) -9.68%
Aug-06-23 07:14AM
10 Oversold Value Stocks To Buy
(Insider Monkey)
Aug-04-23 06:40PM
Aptevo Therapeutics Inc. Announces Closing of Previously Announced $5 Million Public Offering
(ACCESSWIRE)
10:15PM Loading…
Aug-01-23 10:15PM
Aptevo Therapeutics Inc. Announces Pricing of $5 Million Public Offering
(ACCESSWIRE) -5.77%
Jul-30-23 02:17PM
7 Millionaire-Maker Penny Stocks to Buy Before the Window Closes
(InvestorPlace)
Jul-18-23 08:05AM
Aptevo Announces Positive Duration of Remission Data from Phase 1b Expansion Trial Evaluating the Bispecific APVO436 for AML
(ACCESSWIRE) -23.24%
May-11-23 08:05AM
Aptevo Therapeutics Reports 1Q23 Financial Results and Provides Business Update
(ACCESSWIRE)
Apr-01-23 08:51AM
Aptevo Therapeutics Full Year 2022 Earnings: EPS Beats Expectations
(Simply Wall St.)
Mar-30-23 07:45AM
Aptevo Therapeutics Reports 2022 Financial Results and Provides Business Update
(ACCESSWIRE)
07:30AM
Aptevo Therapeutics Raises $9.6 Million in Non-Dilutive Funding
(ACCESSWIRE)
Mar-29-23 10:13AM
12 Cheap Healthcare Stocks to Buy in 2023
(Insider Monkey) +6.88%
Mar-03-23 06:57PM
The Top 7 Growth Stocks in Biotech
(InvestorPlace)
Feb-13-23 08:05AM
Alligator Bioscience & Aptevo Therapeutics Announce Dosing of First Patient with ALG.APV-527 in Phase 1 Clinical Trial
(ACCESSWIRE)
Jan-09-23 08:05AM
Aptevo Therapeutics Files Provisional Patent for Fifth Bispecific Antibody APVO711, Intended for the Treatment of Solid Tumors
(ACCESSWIRE) +6.42%
Dec-12-22 09:54AM
Aptevo Stock Jumps As Acute Myeloid Leukemia Combo Therapy Achieves 100% Clinical Benefit Rate
(Benzinga) +12.58%
07:35AM
100% Clinical Benefit Rate Achieved in Phase 1b Trial Evaluating APVO436 in Combination with Venetoclax and Azacitidine for Venetoclax Treatment Naïve Patients with Acute Myeloid Leukemia (AML)
(ACCESSWIRE)
Nov-10-22 08:05AM
Aptevo Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
(ACCESSWIRE)
Nov-09-22 08:05AM
Alligator Bioscience & Aptevo Therapeutics Announce Publication Highlighting ALG.APV-527 Preclinical Data in Peer-Reviewed Journal Molecular Cancer Therapeutics
(ACCESSWIRE)
09:06AM Loading…
Nov-03-22 09:06AM
Aptevo Therapeutics Announces Poster Presentation at the 64th American Society of Hematology Annual Meeting and Exposition
(ACCESSWIRE)
Sep-19-22 08:45AM
Alligator Bioscience and Aptevo Therapeutics Announce that FDA has Issued a "May Proceed" Notification for the ALG.APV-527 IND
(ACCESSWIRE)
Aug-11-22 08:05AM
Aptevo Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
(ACCESSWIRE)
Jun-09-22 08:05AM
Aptevo Therapeutics Announces New Preliminary Remission Data on Four Additional Patients Enrolled in On-going APVO436 Dose Expansion Phase 1b Trial for the Treatment of Acute Myeloid Leukemia
(ACCESSWIRE) -14.44%
May-12-22 08:05AM
Aptevo Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights
(ACCESSWIRE) +11.26%
Apr-12-22 08:05AM
APVO442 Prostate Cancer Data Presented at the American Association for Cancer Research Annual Meeting
(ACCESSWIRE)
Mar-29-22 08:05AM
Aptevo Therapeutics Announces Monotherapy Patient Received a Transplant in APVO436 Expansion Trial for the Treatment of Acute Myeloid Leukemia
(ACCESSWIRE)
Mar-24-22 08:05AM
Aptevo Therapeutics Reports 2021 Financial Results and Provides Business Update
(ACCESSWIRE) +32.82%
Feb-09-22 08:05AM
Aptevo Therapeutics Earns $10 Million Non-Dilutive Milestone Payment on Sales of RUXIENCE, Provides Company Update
(ACCESSWIRE) +5.62%
Jan-21-22 08:05AM
Aptevo Therapeutics' Board Chairman, Fuad El-Hibri, Announces Retirement, Effective April 1, 2022
(ACCESSWIRE) -6.51%
Dec-15-21 08:05AM
Alligator Bioscience & Aptevo Therapeutics Announce Co-Publication in Peer-Reviewed Journal, "Nature Communication"
(ACCESSWIRE)
Dec-10-21 05:38PM
Towercrest Capital Management Buys Aptevo Therapeutics Inc, PowerShares QQQ Trust Ser 1, ...
(GuruFocus.com) -5.13%
Nov-23-21 08:05AM
Aptevo Therapeutics Reports First Complete Remission, Providing Clinical Update for Its Phase 1b Multi Center, Multi Cohort Expansion Trial in the Treatment of Acute Myeloid Leukemia
(ACCESSWIRE) +162.81%
07:59AM
Aptevo Therapeutics Stock More Than Doubles After Leukemia Study News
(Investing.com)
Nov-15-21 08:05AM
Aptevo Therapeutics Announces the Presentation of Two Abstracts at the Upcoming American Society of Hematology Annual Meeting
(ACCESSWIRE) -16.49%
Nov-12-21 08:05AM
Aptevo Therapeutics Reports Third Quarter Financial Results With Business Highlights
(ACCESSWIRE) -8.71%
Nov-11-21 04:45PM
Alligator Bioscience and Aptevo Therapeutics Announce a Poster Presentation of ALG.APV-527 at SITC Annual Meeting 2021
(ACCESSWIRE)
08:30AM
Aptevo Therapeutics Announces Preclinical Data for Bispecific Antibody APVO603 at the Society for Immunology in Cancer Annual Meeting
(ACCESSWIRE)
Nov-02-21 09:00AM
BriaCell Appoints Renowned Pharmaceutical Veteran Jane Gross, Ph.D. to its Board of Directors
(GlobeNewswire)
Oct-27-21 08:05AM
Aptevo Therapeutics Presents Promising Clinical Data on Its Lead Leukemia Drug Candidate APVO436 at The Second Virtual Conference on Controversies in Leukemias, Euroleuk2021
(ACCESSWIRE)
Oct-26-21 08:05AM
Aptevo Therapeutics Reports in the Refereed Medical Journal Cancers That the Risk of Cytokine Release Syndrome Is Low for Blood Cancer Patients Treated With Its Bispecific Antibody APVO436
(ACCESSWIRE)
Sep-28-21 08:05AM
Aptevo Therapeutics Announces Publication of a Scientific Article in Peer-Reviewed Journal, Frontiers in Aging
(ACCESSWIRE)
Aug-17-21 08:05AM
Aptevo Therapeutics Announces APVO436 Monotherapy is Active in Patients Who Have Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome
(ACCESSWIRE)
Aug-12-21 08:05AM
Aptevo Therapeutics Reports Second Quarter Financial Results with Business Highlights
(ACCESSWIRE) -6.86%
Jul-16-21 08:05AM
Aptevo Therapeutics' Chief Scientific Officer, Jane Gross, PhD, to Present at Upcoming Cambridge Health Institute PEGS Virtual Conference
(ACCESSWIRE) +6.70%
Jun-29-21 08:05AM
Aptevo Therapeutics Announces Inclusion in the Russell Microcap(R) Index
(ACCESSWIRE)
May-27-21 09:00AM
Aptevo Therapeutics Announces Expansion Phase of Lead Anti-Leukemia Drug APVO436 in Adult Patients with Acute Myeloid Leukemia
(ACCESSWIRE)
May-26-21 09:32AM
Aptevo Stock Gains on Encouraging Single-Agent Activity for APVO436 In Leukemia Patients
(Benzinga)
09:00AM
Aptevo Therapeutics Reports Positive Phase 1 Clinical Data for Its Lead Leukemia Drug Candidate APVO436 in Adults With Relapsed Acute Myeloid Leukemia
(ACCESSWIRE)
May-17-21 06:00AM
American Eagle Completes Magnetotelluric Survey at its Golden Trend Property in the Cortez, Nevada; Publishes Interview with CEO Anthony Moreau and VP of Exploration Mark Bradley
(PR Newswire)
May-11-21 09:00AM
Aptevo Therapeutics Reports First Quarter 2021 Financial Results
(ACCESSWIRE)
Apr-09-21 09:00AM
Aptevo Therapeutics to Present at the American Association for Cancer Research Virtual Annual Meeting
(ACCESSWIRE)
Mar-31-21 08:00AM
Aptevo Therapeutics Reports 2020 Financial Results and Provides Business Update
(ACCESSWIRE) +8.23%
Feb-09-21 07:30PM
Aptevo Confirms Receipt of Nominations and Proposal Notice
(ACCESSWIRE) +10.99%
Jan-11-21 08:00AM
Aptevo Therapeutics Provides Update on Ongoing APVO436 Phase 1 Clinical Trial
(ACCESSWIRE)
Jan-06-21 12:00PM
Aptevo Therapeutics Inc. (APVO) Upgraded to Buy: Here's Why
(Zacks)
Dec-19-20 01:45PM
Kaskela Law LLC Announces Investigation of Aptevo Therapeutics Inc. (APVO) and Encourages Shareholders to Contact the Firm
(ACCESSWIRE)
Dec-02-20 08:00AM
Aptevo Therapeutics Announces the Launch of Its Second Platform Technology ADAPTIR-FLEX(TM) and Introduces the New Bispecific Prostate Cancer Candidate APVO442
(ACCESSWIRE) +8.30%
Nov-20-20 07:37AM
The Daily Biotech Pulse: Amarin Surges On Vascepa Data, Mesoblast Rallies On Novartis Deal, Decision Day For Eiger
(Benzinga)
Nov-19-20 04:15PM
Aptevo Confirms Receipt of Unsolicited Indication of Interest
(ACCESSWIRE) +29.10%
Nov-16-20 08:00AM
Aptevo Therapeutics and Alligator Bioscience Advancing the Bispecific 4-1BBx5T4 Antibody ALG.APV-527 Into Phase 1 Clinical Development
(ACCESSWIRE) -8.85%
Nov-10-20 08:40AM
The Daily Biotech Pulse: Lilly's COVID-19 Antibody Treatment Approved For Emergency Use, Supernus Faces Twin Regulatory Setbacks, Revance, Arena Flunk Midstage Studies
(Benzinga) +35.37%
Nov-09-20 09:00AM
Aptevo Therapeutics to Present at the Society for Immunotherapy of Cancer's (SITC) 35th Virtual Annual Meeting
(ACCESSWIRE) +38.14%
06:00AM
Aptevo Therapeutics Announces Second Complete Remission in Ongoing APVO436 Phase 1 Clinical Trial
(ACCESSWIRE)
Nov-08-20 11:15PM
Aptevo Therapeutics Adopts Limited Duration Stockholder Rights Plan
(ACCESSWIRE)
Nov-03-20 09:00AM
Aptevo Therapeutics Announces First Complete Remission in Ongoing APVO436 Phase 1 Clinical Trial
(ACCESSWIRE) +78.25%
Sep-01-20 09:00AM
Aptevo Therapeutics Provides Update on Ongoing APVO436 Phase 1 Clinical Trial
(ACCESSWIRE)
Aug-14-20 09:00AM
Aptevo Therapeutics Reports Second Quarter 2020 Financial Results
(ACCESSWIRE) +7.85%
Aug-06-20 09:00AM
Aptevo Therapeutics Secures $25 Million Non-Dilutive Financing from Midcap Financial Trust
(ACCESSWIRE)
Jul-21-20 09:00AM
Aptevo Therapeutics Engages Piper Sandler to Sell its RUXIENCE(R) and IXINITY(R) Royalty Streams & Milestones
(ACCESSWIRE)
Jun-30-20 12:00PM
All You Need to Know About Aptevo Therapeutics Inc. (APVO) Rating Upgrade to Buy
(Zacks) -9.92%
11:30AM
Has Aptevo Therapeutics (APVO) Outpaced Other Medical Stocks This Year?
(Zacks)
Jun-29-20 09:00AM
Aptevo Therapeutics Collects $750,000 Working Capital Escrow From Medexus Related to IXINITY(R) Sale
(ACCESSWIRE) +13.05%
Jun-25-20 09:00AM
Aptevo Therapeutics to receive Seven Year Quarterly Royalty Payment Stream from Pfizer for Sales of Rituximab Biosimilar
(ACCESSWIRE) +55.83%
Jun-10-20 09:00AM
Aptevo Therapeutics and Alligator Bioscience Present New Preclinical Data for ALG.APV-527 at the PEGS Virtual Interactive Global Summit
(ACCESSWIRE)
May-13-20 09:00AM
Aptevo Therapeutics Reports First Quarter 2020 Financial Results
(ACCESSWIRE) -7.11%
Apr-14-20 09:00AM
Aptevo Therapeutics Regains Compliance With Nasdaq Listing Requirements
(ACCESSWIRE) +15.20%
Mar-25-20 09:00AM
Aptevo Therapeutics Reports 2019 Financial Results and Provides Business Update
(ACCESSWIRE)
Mar-16-20 09:00AM
Aptevo Therapeutics Provides Update On Ongoing APVO436 Phase 1 Clinical Trial
(ACCESSWIRE) +19.11%
Feb-28-20 09:05AM
Aptevo Therapeutics Sells IXINITY Hemophilia B Therapy for Estimated Proceeds in Excess of $100 Million
(ACCESSWIRE) +8.89%
08:59AM
Medexus Expands its US Product Portfolio by Acquiring the Hematology Asset IXINITY®
(GlobeNewswire)
Jan-30-20 09:00AM
Aptevo Therapeutics Doses First Patient in IXINITY Clinical Trial for Potential Pediatric Label Expansion
(ACCESSWIRE)
Jan-13-20 08:00AM
Aptevo Therapeutics' APVO436 Selected For Inclusion In The Leukemia & Lymphoma Society's Groundbreaking BEAT AML(R) Master Clinical Trial
(ACCESSWIRE)
Dec-19-19 03:50PM
Aptevo Therapeutics Inc. (APVO): Are Hedge Funds Right About This Stock?
(Insider Monkey)
Dec-06-19 09:00AM
Aptevo Therapeutics Receives Orphan Drug Designation for APVO436 for the Treatment of Acute Myelogenous Leukemia
(GlobeNewswire)
Nov-12-19 09:00AM
What Makes Aptevo Therapeutics Inc. (APVO) a New Buy Stock
(Zacks)
Nov-08-19 09:00AM
Aptevo Therapeutics and Alligator Bioscience Present New Preclinical Data for ALG.APV-527 at the Society for Immunotherapy of Cancer 2019 Annual Meeting
(GlobeNewswire) +7.39%
Nov-07-19 09:00AM
Aptevo Therapeutics Reports Third Quarter 2019 Financial Results
(GlobeNewswire)
Oct-04-19 07:32AM
The Daily Biotech Pulse: Arbutus Halts Hepatitis B Study, Positive Readout For MEI Pharma's Blood Cancer Drug, Ovid Offering
(Benzinga) +6.93%
Oct-03-19 04:02PM
Aptevo Therapeutics Provides Corporate and Pipeline Update
(Globenewswire Test)
Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on developing novel immunotherapies for the treatment of cancer. Its pipeline APVO436, ALG.APV-527 and APVO603 were developed based on the ADAPTIR modular protein platform technology and APVO442 was developed based on the new ADAPTIR-FLE platform technology. The ADAPTIR and ADAPTIR-FLEX are capable of generating differentiated bispecific and multi-specific antibodies with potentially unique mechanisms of action for the treatment of different types of cancer. The company was founded in February 2016 and is headquartered in Seattle, WA.
open in screener | open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.